Astria Therapeutics (NASDAQ:ATXS) Cut to Neutral at Cantor Fitzgerald

Astria Therapeutics (NASDAQ:ATXS) was downgraded by Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued on Wednesday, MarketBeat Ratings reports.

Several other equities analysts also recently weighed in on ATXS. Weiss Ratings reissued a “sell (d-)” rating on shares of Astria Therapeutics in a research report on Wednesday, October 8th. Evercore ISI reiterated an “outperform” rating and set a $26.00 price objective on shares of Astria Therapeutics in a research report on Wednesday, October 1st. JMP Securities restated a “market perform” rating on shares of Astria Therapeutics in a report on Wednesday, October 15th. Citizens Jmp downgraded shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 15th. Finally, Oppenheimer downgraded shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $25.00.

Astria Therapeutics Trading Up 0.2%

Shares of NASDAQ:ATXS traded up $0.03 during midday trading on Wednesday, hitting $12.54. 972,113 shares of the stock were exchanged, compared to its average volume of 740,004. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $12.72. The company has a 50 day moving average price of $9.55 and a 200-day moving average price of $7.07. The stock has a market cap of $707.41 million, a P/E ratio of -6.24 and a beta of 0.21.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.13). On average, equities research analysts expect that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Trading of Astria Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP lifted its position in shares of Astria Therapeutics by 8.2% during the second quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company’s stock worth $24,238,000 after purchasing an additional 342,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in Astria Therapeutics by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,642,170 shares of the biotechnology company’s stock valued at $19,235,000 after purchasing an additional 117,510 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Astria Therapeutics by 4,607.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock worth $9,091,000 after buying an additional 1,660,039 shares during the period. Nantahala Capital Management LLC lifted its holdings in Astria Therapeutics by 59.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company’s stock worth $5,733,000 after buying an additional 400,000 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in Astria Therapeutics by 48.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 875,000 shares of the biotechnology company’s stock worth $4,690,000 after buying an additional 286,800 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.